New Delhi: The Drugs Controller General of India (DCGI) on Saturday (May 8, 2021) accredited drug 2-deoxy-D-glucose (2-DG) which is developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), DRDO in collaboration with Dr Reddy’s Lab.
The medical trial outcomes have proven that this molecule helps in quicker restoration of hospitalised sufferers and reduces supplemental oxygen dependence. Higher proportion of sufferers handled with 2-DG confirmed RT-PCR unfavourable conversion in sufferers contaminated with coronavirus.
The drug is anticipated to be of immense profit to the individuals affected by COVID-19 within the ongoing pandemic.
Being a generic molecule and analogue of glucose, it may be simply produced and made obtainable in massive portions within the nation.
The drug is available in a sachet in powder kind, which is taken orally by dissolving it in water.
It accumulates within the virus contaminated cells and prevents virus development by stopping viral synthesis and vitality manufacturing. Its selective accumulation in virally contaminated cells makes this drug distinctive.
Meanwhile, India on Friday reported over 4.01 lakh (4,01,078) contemporary COVID-19 instances and greater than 4 thousand instances within the final 24 hours.
4,187 individuals succumbed to the lethal an infection, the best variety of fatalities in a single day, as per the Union Health Ministry information on Saturday (May 8). The whole caseload surpassed the two.18-lakh mark (2,18,92,676), whereas the demise rely climbed to 2,38,270.
